18FDOPA / DOPACIS™ is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum: To help differentiate probable dementia with Lewy bodies from Alzheimer’s disease. DOPACIS™ is unable to discriminate between dementia with Lewy bodies and Parkinson’s disease dementia
